article thumbnail

UK ATMP clinical trials report 2022 published

European Pharmaceutical Review

The Cell and Gene Therapy (CGT) Catapult has published its ‘ UK Advanced Therapy Medicinal Products (ATMP) Clinical Trials Report 2022 ’. The research observed this cell type took up 58 percent of UK ATMP clinical trials in 2022. . The number of Phase II/III trials increased from three trials in 2021 to seven trials in 2022.

article thumbnail

STAT’s most memorable photos of 2022

STAT

Reflecting back on our favorite photographs from 2022, we are struck by how many portraits were in our selection. These images also document a pipeline program for Indigenous medical students, an incarcerated person fighting for better hepatitis C care, and a trailblazing Alzheimer’s researcher.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Regulation, particularly Annex 1, was identified as a key focus for 2022.

Vaccines 128
article thumbnail

STAT+: Hospital systems’ investment income perked up at end of 2022

STAT

Large hospital systems’ investments rebounded heavily in the final quarter of 2022, according to a new STAT analysis of financial filings. STAT analyzed the financial documents of 37 tax-exempt, not-for-profit health systems covering the last three months of 2022.

article thumbnail

Intas Pharmaceuticals under FDA scrutiny after oversight in GMP documents

Pharmafile

India-based manufacturer Intas Pharmaceuticals has been issued a Form 483 by the FDA after three investigators found a “cascade of failure” in a site inspection carried out at their manufacturing facility in Pharmez Special Economic Zone (SEZ) between late November and early December 2022. read more

article thumbnail

2022 WHO Biosimilar Guideline improves access, IGBA says

European Pharmaceutical Review

The International Generic and Biosimilar Medicines Association (IGBA)’s new whitepaper Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline suggests how the guideline provides great opportunity to revaluate how regulatory requirements can better advance biosimilar access. WHO Biosimilar Guideline updates.

article thumbnail

Filings buzz in pharmaceuticals: 65% increase in cloud computing mentions in Q1 of 2022

Pharmaceutical Technology

Mentions of cloud computing within the filings of companies in the pharmaceutical industry rose 65% between the final quarter of 2021 and the first quarter of 2022. Of the 10 biggest employers in the pharmaceutical industry, IQVIA was the company which referred to cloud computing the most between April 2021 and March 2022.